
    
      This is a pilot study to determine the feasibility of a novel combination of Pembrolizumab
      and Decitabine in relapsed/refractory adult AML patients. While both Pembrolizumab and
      Decitabine are FDA approved agents, this study will explore giving these drugs in combination
      for this population of patients.
    
  